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Background: Percutaneous renal artery angioplasty and/or stenting (RA-PTAS) is increasingly being used as an
alternative to surgery for renal artery revascularization. Unfortunately, renal function responses after RA-PTAS appear
to be inferior to those observed after surgical revascularization both in terms of improving and preventing deterioration
of renal function postintervention. Atheroembolism during RA-PTAS has been postulated as a potential cause for the
disparate results. Strategies to limit the occurrence of atheroembolism, such as the use of distal embolic protection (DEP)
systems, may result in improved outcomes after RA-PTAS.
Methods: All RA-PTAS procedures performed with DEP (using a commercially available temporary balloon occlusion and
aspiration catheter) between October 2003 and July 2005 were reviewed. Glomerular filtration rate (eGFR) was
estimated preintervention and 4 to 6 weeks postintervention using the abbreviated Modification of Diet in Renal Disease
formula. Renal function and hypertension response rates as well as procedural data were classified and reported according
to American Heart Association guidelines. Renal function improvement and deterioration were defined as a 20% increase
and decrease in eGFR, respectively, compared with preoperative values. Continuous and categoric data were analyzed
using paired t tests and repeated measures linear models.
Results:DEPwas used in 32 RA-PTAS procedures in 15 women and 11menwith amean age of 71 years. All patients were
hypertensive, 24 (92%) had renal insufficiency, and the mean preintervention degree of renal artery stenosis was 79%.
Immediate technical success was achieved in 100% of RA-PTAS cases. Mean pre- and postintervention serum creatinine
and eGFR values were 1.9 vs 1.6 mg/dL (P < .001) and 37 vs 43 mL/min/1.73 m2 (P < .001), respectively. Renal
function was defined as improved after 17 (53%) of 32 procedures and worsened in none (0%).
Conclusions: RA-PTAS using DEP resulted in 4- to 6-week postintervention renal function results approximating those
of surgical revascularization. These data suggest that DEP use may prevent renal function harm during RA-PTAS as a
result of atheroembolism and warrant further investigation. (J Vasc Surg 2006;44:128-35.)Atherosclerotic renovascular disease (RVD) is increas-
ingly recognized as a cause of severe secondary hyperten-
sion, excretory renal insufficiency, and end-stage renal dis-
ease by reducing renal blood flow. RVD represents an
important public health problem, as all of these associated
conditions have been demonstrated to increase cardiovas-
cular and all-cause mortality.1-5 Percutaneous transluminal
angioplasty and stenting of the renal artery (RA-PTAS) as
well as open surgical revascularization can be used to re-
store perfusion to affected kidneys. RA-PTAS has become
the more frequently used treatment method in most
centers and has demonstrated beneficial effects in im-
proving control of renovascular hypertension in selected
patients.6-10 However, reported results have been less
favorable in improving associated renal insufficiency,6-10
which is the major determinant of subsequent car-
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128diovascular morbidity and mortality as well as dialysis-
dependence.11-13
We hypothesize that atheroembolization of the renal
parenchyma is a major, preventable factor limiting the
benefits derived from RA-PTAS. This hypothesis is sup-
ported by recent ex vivo data from RA-PTAS procedures
performed on aortorenal endarterectomy specimens.14
Distal embolic protection (DEP) devices, balloon or ex-
pandable filter-tipped guidewires that can be positioned
distal to the lesion selected for treatment, have been re-
cently developed and approved for use in the coronary and
cerebral circulations to prevent distal passage of liberated
debris. Use of such devices in the performance of RA-PTAS
may increase the rate of beneficial clinical responses after
revascularization. This report details a single-center experi-
ence with the use of a commercially available temporary
distal balloon occlusion and aspiration DEP system during
RA-PTAS.
METHODS
Patient population. This investigation was conducted
with approval from the Wake Forest University Health Sci-
ences Institutional Review Board. All RA-PTAS procedures
performed between October 2003 and July 2005 were
identified through an institutional registry. RA-PTAS was
performed only in patients with hemodynamically signifi-
cant atherosclerotic RVD (60% diameter-reducing steno-
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phy) and severe hypertension, with or without associated
excretory renal insufficiency. Case records for all individuals
undergoing RA-PTAS with attempted DEP use were se-
lected for review. Only those individuals with 4 weeks of
follow-up were included in this report.
Materials reviewed. All outpatient clinic, hospital,
noninvasive vascular laboratory, and endovascular operat-
ing suite records were reviewed. Collected data included
information regarding preoperative demographics, anthro-
pometrics, and medical comorbidities as well as indication
for revascularization, procedural specifics, complications,
postoperativestatus,andpostoperativerenalarterypatency/
restenosis. The percentage of renal artery stenosis was
calculated from angiographic images in a fashion congruent
with that described in the Asymptomatic Carotid Athero-
sclerosis Study.15 All collected data were entered into an
electronic database.
Operative management. Patients were admitted on
the day before RA-PTAS to a 23-hour day hospital for hydra-
tion and oral administration of 600 mg of N-acetylcysteine
every 12 hours. RA-PTAS procedures were performed in an
endovascularly equipped operating suite. Only one renal
artery lesion was treated at any given procedural setting.
Bilateral lesions were treated in a staged fashion, with
interventions performed at least 4 weeks apart to minimize
the volume administered and nephrotoxic effects of iodin-
ated contrast and avoid the potential for bilateral ischemic
renal complications.
Femoral sheath access was used for all procedures re-
ported here, and intravenous heparin was administered (50
to 100 U/kg per surgeon preference) once access was
secured. Iodinated and non-iodinated (carbon dioxide)
contrast materials were used. In patients with severe renal
insufficiency, carbon dioxide was used to initially localize
and cannulate the renal artery, followed by hand injection
of dilute (half-strength) iodinated contrast for treatment
planning once selective cannulation was achieved.
Selective cannulation of the renal arteries was accom-
plished using a minimal contact technique of ostial engage-
Fig 1. Photograph of the Medtronic Guardwire temporary bal-
loon occlusion distal embolic protection system. (Used with per-
mission from Medtronic AVE, Minneapolis Minn.)ment with an angled guiding catheter telescoped through a10-cm 6F sheath. The lesion to be treated was not crossed
with the guide catheter. Guidewire crossing of the lesion
was performed using a commercially available temporary
balloon occlusion and aspiration 0.014-inch DEP guide-
wire system (Guardwire, Medtronic AVE, Minneapolis
Minn) (Fig 1). The Guardwire was chosen because of its
ability to completely occlude the renal artery and, hope-
fully, prevent the passage of debris too small for retention
by existing filter designs that currently have a porosity of no
less than 100 m. Preintervention pressure gradients were
not measured to minimize manipulations across the lesion.
The distal occlusion balloon was inflated in the distal
main renal artery immediately after crossing the lesion, and
occlusion was confirmed by hand injection of contrast
(Fig 2). RA-PTAS was then performed using angioplasty
balloons, balloon-mounted stents (Genesis, Cordis, Miami
Lakes, Fla; Express, Boston Scientific, Natick, Mass; and
Racer, Medtronic), or self-expanding stents (Wallstent,
Boston Scientific) of operator choice sized to match the
distal, normal appearing renal artery.
Predilation angioplasty was performed at the discretion
of the operating surgeon. All predilation angioplasty was
performed with the Guardwire in place and inflated. Stents
were positioned to extend 1 to 2 mm into the aortic lumen
while completely covering the lesion to be treated. After
stent deployment, the static column of blood proximal to
the temporary occlusion balloon was evacuated using a
rapid exchange Export aspiration catheter (Medtronic
AVE) (Fig 3). After 60 mL of blood was aspirated, the
aspiration catheter was used to inject at least 20 mL of
heparinized, injectable, sterile 0.9% saline to flush any
Fig 2. Hand injection angiogram demonstrates complete renal
artery occlusion using the distal embolic protection system before
stent placement.residual debris from the renal artery.
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completion renal arteriography performed. Pull-back pres-
sure gradients or intraoperative duplex scans, or both, were
performed in all cases to assess the hemodynamic effects of
the procedure.
Routine follow-up included clinic visits at 4 weeks, 3
months, 6months, and 1 year to assess clinical response and
revascularization durability. Studies obtained at each visit
included renal duplex sonography and measurement of
serum creatinine levels.
Outcomemeasures and reporting. All outcome mea-
sures were reported in accordance with consensus re-
porting guidelines.16 Renal function was evaluated using
the abbreviated Modification of Diet in Renal Disease
formula17 for estimated glomerular filtration rate (eGFR)
calculated from preoperative and postoperative serum cre-
atinine concentration: eGFR/1.73 m2  186  (serum
creatinine)1.154  (age)0.203  (0.742 if female) 
(1.210 if African American).17
Post revascularization renal function was assessed at the
4- to 6-week follow-up to allow for the effects of perioper-
ative volume expansion and contrast administration to re-
solve. This follow-up time point was chosen due to its
coincidence with routinely scheduled follow-up used by
our group. Renal function was considered improved if a
20% increase in eGFR was observed after RA-PTAS and
worsened if a20% decrease in eGFR was observed. Renal
function was defined as unchanged if the criteria for im-
proved or worsened function were not met. Renal function
responses were reported on both a per-patient (considering
bilateral staged interventions as a single treatment) and
per-procedure basis.
Blood pressure response was also assessed at the 4- to
6-week follow-up using the highest measured brachial
blood pressure pre- and postoperatively taken in a sitting
position. Blood pressure response was defined as follows:
cured—diastolic blood pressure (DBP) 90 mm Hg and
systolic blood pressure (SBP) 140 mm Hg off all antihy-
Fig 3. Photograph of the Medtronic Export catheter for aspira-
tion of atheroembolic debris. (Used with permission from
Medtronic AVE, Minneapolis, Minn.)pertensive medications; improved—DBP 90 mm Hg orSBP 140 mm Hg, or both, on the same or reduced
number of medications or a reduction in DBP of 15 mm
Hg on the same or a reduced number of medications;
failed—no change or inability to meet the criteria for cure
or improvement. Blood pressure responses were also re-
ported on both a per-patient and per-procedure basis.
Renal artery patency was evaluated using renal duplex
sonography. Renal artery patency was defined as the ab-
sence of occlusion (defined as lack of a Doppler shifted
signal from an imaged renal artery) on follow-up examina-
tion. Primary and primary-assisted patencies were exam-
ined. Restenosis during follow-up was defined as renal
duplex sonography evidence of recurrent hemodynamically
significant renal artery stenosis (defined as renal artery peak
systolic velocity of 1.8 m/s or more18) on surveillance
duplex sonography. Freedom from hemodynamically sig-
nificant restenosis was also examined.
Statistical methods. Descriptive statistics (means 
standard deviations of continuous variables, frequencies
and relative frequencies of categoric variables) were com-
puted. Analyses of pre- to postoperative changes in patient-
based responses (considering staged interventions as a
single treatment) were performed using paired t tests.
Procedure-based analyses of pre- to postoperative changes
in responses were analyzed using maximum-likelihood re-
peated measures linear models assuming compound sym-
metry covariance structure.19 Postoperative renal artery
patency rates were estimated using product-limit methods.
RESULTS
Study group. During the study period, 27 individuals
underwent RA-PTAS with DEP for atherosclerotic RVD.
One patient was lost to follow-up. The resultant study
group consisted of 15 women and 11 men with a mean age
of 71 years. The mean preoperative serum creatinine value
was 1.9 mg/dL, and eGFR was 37 mL/min/1.73 m2.
Moderate-to-severe preoperative renal insufficiency was
present in 24 patients (92%) (eGFR 60 mL/min/
1.73 m2), including 9 (35%) with eGFR 30 mL/min/
1.73 m2. No patient was dialysis-dependent. All patients
were hypertensive (mean preoperative SBP of 175 mm Hg
and DBP of 81 mm Hg) with a mean antihypertensive
agent usage of 3.4medications. Demographics andmedical
comorbidity data for the 26 study group patients are sum-
marized in Table I.
Procedural data. The 32 RA-PTAS procedures per-
formed during the study period included 29 stent proce-
dures and three primary angioplasty procedures (including
two for restenosis). Treated were 25 primary atheroscle-
rotic lesions and seven restenotic lesions (five from prior
RA-PTAS procedures, one stenotic renal artery bypass, and
one stenosis following renal artery endarterectomy). Renal
artery lesions were located at the ostium in 26 cases and in
the main renal artery in six (including five cases of in-stent
restenosis). Mean renal artery diameter pretreatment was
5.8 mm (range, 4.3 to 7.5 mm).
Eighteen patients were treated for unilateral disease
and four patients for bilateral disease, including one patient
d glo
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patients demonstrated contralateral renal artery occlusions,
and 10 demonstrated contralateral stenosis 60%.
Iodinated non-ionic contrast was used in all cases
(mean volume administered, 84 mL), and carbon dioxide
was an adjunct in four. The mean degree of pre- and
postoperative stenosis was 79% and 1%. Temporary balloon
occlusion was complete in 28 cases (88%), and visible debris
was noted in the aspirated blood in 14 (44%). Immediate
technical success, in terms of lesion revascularization, was
achieved in all cases. Procedural data for all 32 RA-PTAS
procedures are summarized in Table II.
Complications. A significant complication, a femoral
pseudoaneurysm that required thrombin injection, oc-
curred in one patient (3%). No complications specifically




Caucasian race 24 (92)







Moderate renal insufficiency 15 (57)
Severe renal insufficiency 9 (35)
Coronary artery disease 13 (50)
Diabetes mellitus 9 (35)
COPD 2 (8)
SBP, Systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimate







Significant contralateral RVD 14 (54)
Predilation necessary 8 (25)
Stent diameter (mm)
4 mm 2 (7)
5 mm 8 (28)
6 mm 18 (62)








Iodinated contrast used (mL)
RVD, Renovascular disease.related to use of the DEP device were observed.Renal function response at 4 to 6 weeks. Pre- and
postoperative serum creatinine and eGFR data are summa-
rized in Table III. A significant decrease in the serum
creatinine value and a significant increase in eGFR were
observed. Renal function response at the 4- to 6-week
follow-up was defined as improved in 13 patients (50%) and
after 17 RA-PTAS procedures (53%), and unchanged in 13
patients (50%) and after 15 RA-PTAS procedures (47%). In
no patient or after any procedure was renal function ob-
served to be worsened. Among seven restenotic lesions
treated with DEP, four demonstrated improved renal func-
tion after RA-PTAS. All 13 patients with renal function
improvement post-RA-PTAS demonstrated moderate-to-
severe preoperative renal insufficiency. In total, 13 (54%) of
24 patients with preoperative renal insufficiency demon-
26)
Mean  SD Minimum Maximum
70.7  9.1 48 84
175  23 126 222
81  12 65 111
3.3  0.9 1 5
1.9  0.7 1.1 4
37  14 16 68
merular filtration rate; COPD, chronic obstructive pulmonary disease.
r stenting procedures performed using distal embolic
Mean  SD Minimum Maximum
79  12 60 95
1  4 0 20
54  43 0 100
5.6  0.8 4 8
16.0  3.3 12 24
10.8  7.5 4.8 30.6
84  36 10 156(n sty ostrated improved renal function after RA-PTAS usingDEP.
BP, di
JOURNAL OF VASCULAR SURGERY
July 2006132 Edwards et alBlood pressure response at 4 to 6 weeks. Pre- and
postoperative blood pressure and antihypertensive medica-
tion use data are summarized in Table III. Significant
decreases in SBP, DBP, and in the number of antihyperten-
sive medications were observed. At the 4- to 6-week follow-
up, blood pressure cure was observed in no patients (0%),
improvement in nine (35%), and no change in 17 (65%).
Renal artery patency. Mean follow-up was 25.4
weeks. No renal artery occlusions were observed during
follow-up. At 6 months, estimated primary and primary
assisted renal artery patencies were 100%. Seven cases of
restenosis were observed in six patients, with amean time to
detection of 17 weeks. Four of the restenotic lesions were
confirmed angiographically with repeat treatment (three
with repeat RA-PTAS and one with bypass). Mean renal
artery and initial stent size in these cases were 5.5 mm
(range, 4.3 mm to 7.1 mm) and 5.2 mm (range, 4 mm to 6
mm), respectively. Estimated 6-month freedom from reste-
nosis was 71% (Fig 4). All cases involved in-stent restenosis,
and in no case was the restenotic lesion observed in the
distal main renal artery at the site of DEP balloon inflation.
Follow-up renal function response. Among those
patients with improved renal function post-RA-PTAS, four
Table III. Renal function and blood pressure responses af
performed with distal embolic protection
Pre-op value
Renal function
Serum creatinine (mg/dL) 1.9  0.1
eGFR (mL/min/1.73 m2) 37  3
Blood pressure
SBP (mm Hg) 175  23
DBP (mm Hg) 81  12
Antihypertensive medications (n) 3.4  0.2
eGFR, Estimated glomerular filtration rate; SBP, systolic blood pressure; D
Fig 4. Estimated freedom from restenosis during follow-up.(31%) had deterioration of renal function response to base-line or beyond observed during follow-up. Three of these
patients had renal artery restenosis, the fourth had severe
proteinuria and suspected intrinsic renal parenchymal dis-
ease. Two patients with restenosis and loss of beneficial
renal function response achieved repeat improvement of
renal function after additional RA-PTAS. The third patient
refused further RA-PTAS.
DISCUSSION
This investigation examined a single center experience
with RA-PTAS using a temporary balloon occlusion and
aspiration DEP system, with the goal of decreasing or
eliminating procedural related atheroembolization and
maximizing beneficial renal function responses. At the 4- to
6-week follow-up, a significant decrease in serum creatinine
values and an increase in eGFR were observed for the study
group as a whole. Most of the patients with preoperative
renal insufficiency demonstrated a20% increase in eGFR,
and no patient exhibited a short-term deterioration in renal
function.
These results represent a marked improvement in
short-term renal function response rates after percutaneous
renal artery revascularization compared with previously
published experiences and approximate the short-term re-
sults reported after open surgical revascularization. These
data are intriguing, especially when considered in context
of the population disease burden, changes in treatment
patterns, and renal function effects associated with RVD.
We hypothesize that the renal function effects of
RA-PTAS are strongly affected by atheroembolization that
may occur at the time of procedure. Such atheroemboliza-
tion may limit functional recovery in patients with renal
insufficiency or lead to diminished function in individuals
regardless of preoperative renal function. This hypothesis
was initially tested using an ex vivo preparation of aortore-
nal endarterectomy specimens treated with RA-PTAS.14
Thousands of liberated particles were observed, with an
inverse relationship between particle size and number.
This hypothesis has also been examined indirectly in
two published experiences of RA-PTAS performed with
DEP that reported similar responses in terms of protection
from short-term renal function deterioration.20,21 In these
series, renal function improvement rates approximating
2 renal artery angioplasty or stenting procedures
Post-op value Difference P
1.6  0.1 0.3 .001
43  3 6.6 .001
159  25 15 .004
75  11 5.1 .018
3.1  0.2 0.3 .045
astolic blood pressure.ter 340% were observed, and no acute renal function decline
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in these two reports in which the Guardwire and Angio-
guard (Cordis) were used. In this experience, 44% of cases
had debris at the time of aspirated blood examination. We
suspect that this is a conservative estimate of significant
debris release, given that only visible debris was noted, with
inability to appreciate the smaller fragments that would
appear to be more likely given the ex vivo data.
Recent prevalence estimates indicate that atheroscle-
rotic RVD is present in approximately 7% of the general
elderly population22 and in up to 40% of individuals with
coronary or peripheral vascular disease.23-25 These preva-
lence estimates translate into a current at-risk population of
3 million Americans. RVD is an increasingly recognized
contributor to severe secondary hypertension and excretory
renal insufficiency25-29and is the suspected cause in 10% to
20% of incident cases of dialysis-dependence among indi-
viduals aged  50 years.26,28 In addition to the quality-
of-life issues associated with the progression to dialysis-
dependence, excretory renal insufficiency is an increasingly
recognized risk factor for subsequent cardiovascular mor-
bidity and mortality.2,4,5 Reduction of risk for future ad-
verse cardiovascular events and progression of renal insuffi-
ciency is the ultimate goal of any renal artery revascularization
procedure.
RA-PTAS is increasingly being used to improve renal
perfusion in hopes of ameliorating these problems despite
the lack of any level I evidence supporting its use.30 This
increase in utilization is likely secondary to increased phy-
sician awareness of RVD as a potentially causative factor in
severe hypertension and renal insufficiency as well as the
perception of minimal morbidity associated with RA-PTAS.
Several authors have demonstrated a shift away from open
surgical renal artery revascularization and an increase in
RA-PTAS, with a net total increase in the number of renal
artery interventions performed.30,31 This shift in utilization
patterns and increase in RA-PTAS could be harmful to
patients if RVD treated in this fashion demonstrates a worse
natural history than RVD treated surgically or medically, a
distinct possibility in the era of highly efficacious antihyper-
tensive agents such as angiotensin-receptor blockers and
converting-enzyme inhibitors. This latter possibility is cur-
rently being investigated by the ongoing Cardiovascular
Outcomes in Renal Atherosclerotic Lesions (CORAL)
trial, which will provide critical information to define ap-
propriate treatment in the future.
Until those results are available, however, existing data
must guide contemporary treatment. Recent reports con-
cerning RA-PTAS6-10 have observed short-term renal func-
tion improvement in 15% to 34% of patients and nearly
identical rates of short-term deterioration (range, 8% to
27%). These data are similar to those published in a recent
meta-analysis,32 and they compare poorly with the reported
results of surgical revascularization where short-term renal
function improvement has been observed in 45% to 55% of
patients and deterioration in 5% to 8% of patients.11,13,33,34
Short-term renal function response is an extremely
important outcome, one that has been repeatedly demon-strated as a robust predictor of post-revascularization sur-
vival if improved, and subsequent death or progression to
dialysis, or both, if diminished.11-13,33,34 Changes in eGFR
may be small in absolute terms, especially in patients with
renal insufficiency, but relatively large in terms of overall
residual function. In a report previously published by our
group,11 renal function improved and worsened by 20%
following renal revascularization significantly and indepen-
dently improved and worsened, respectively, dialysis-free
survival across all strata of preoperative renal function.
Renal function unchanged (or “stabilized”) had differ-
ing effects, however, according to the level of preoperative
renal function. In individuals with severe preoperative renal
insufficiency, unchanged renal function predicted a risk of
death or progression to dialysis similar to that observed
with renal function worsened. In individuals with more
normal preoperative renal function, unchanged renal func-
tion predicted similar dialysis-free survival to that observed
with renal function improved.
These results strongly suggest that renal function wors-
ened after revascularization is an adverse outcome in all
patients, regardless of the level of preoperative renal func-
tion. These results also question whether the concept of
stabilized renal function is valid in patients with preopera-
tive renal insufficiency and underscore the potential impor-
tance of the observations we have reported here that use of
DEP was associated with no occurrence of short-term renal
function deterioration.
Observed blood pressure responses, though, were less
promising in this series, with only 35% of patients demon-
strating improvement by American Heart Association guide-
line definitions. Several explanations exist for this observation,
including follow-up too short to allow for detection of
improvement, or coexisting severe essential hypertension
or lack of downregulation of the renin-angiotensin system
due to inadequate RA-PTAS results, or both. Review of our
data did not demonstrate improvement of hypertension
over longer follow-up, and all procedures used either post-
RA-PTAS measurement of pressure gradients or renal du-
plex sonography with remediation of any observed residual
lesions.
We speculate that these observations relate to the refer-
ral source for these patients, primarily nephrologists, and
because almost all of the interventions were performed for
ischemic nephropathy. Patients werewellmanagedwith effec-
tive agents upon presentation, and this patient group has a
high prevalence of severe essential hypertension. Significant
reductions in systolic and diastolic blood pressure as well as
medication usage were observed, but the changes met
guideline definitions in only 35% of individuals.
Follow-up renal function was promising but did dem-
onstrate reason for concern. Of patients exhibiting im-
provement in renal function at 4 to 6 weeks, nearly one
third returned to baseline during follow-up. Restenosis
appeared to be a likely culprit in this process, affecting 75%
of these individuals. Two of the three patients with reste-
nosis demonstrated prompt return to their improved state
after repeat RA-PTAS, and the third refused further treat-
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and deserving of further investigation.
Although these results are promising and intriguing,
this investigation has numerous limitations. Primary renal
function outcomes were measured according to estimated
glomerular filtration equations that have not been previ-
ously validated in individuals with RVD. Ideally, direct
measures of renal function effect would be employed.
Another weakness is that most patients demonstrated
bilateral RVD, but most of the interventions were unilat-
eral. Several patients had planned second interventions that
were performed after the time of data accumulation for this
review; however, most had clinical responses that were
significant and precluded contralateral intervention based
upon our usual clinical indications. This may have led to an
underestimation of the renal function effects of routine
DEP use.
Conversely, the relatively small number of patients
detailed in this investigation limited the expected num-
ber of adverse events observed and potentially increased
the chance of a spurious observation of positive results. A
similar limitation may have been present in the number
of restenotic lesions included, as they may possess a
lower atheroembolic potential than primary atheroscle-
rotic lesions.
Patient numbers may also have limited the occurrence
of anatomy not amenable to the use of the Guardwire. The
design of the Guardwire precludes its use in individuals
with long renal artery lesions or early renal artery bifurca-
tions that will not allow for its deployment and in cases
where the distal renal artery is 6 mm in diameter. Such
anatomy was not observed in this series, but it is certain to
occur with widespread use.
It is also possible that the beneficial renal function
responses observed were partly or totally secondary to
improvements in periprocedural renal protective measures
such as hydration and N-acetylcysteine administration.
The most important limitation to this study, though, is
that this report is a retrospective review of clinical practice
and not a prospective, randomized clinical trial. Rigorous
exam of this concept with a non-DEP comparison group is
mandatory before widespread recommendation of DEP use
can be made.
CONCLUSION
These limitations notwithstanding, this investigation
presents promising results that deserve further investiga-
tion. We hope all of these limitations will be addressed, and
the overriding question concerning the utility of DEP in
renal artery PTAS will be answered by a well-designed
randomized, clinical trial.
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